A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients

摘要: Objectives Low-dose stavudine therapy may have a lower toxicity profile compared with standard dose. A randomized controlled trial comparing these two doses of tenofovir disoproxil fumarate (tenofovir DF) was performed to assess the effects on anthropometry, markers inflammation, and lipid glucose metabolism in Black South African patients. Methods Sixty patients were 1:1:1 either standard-dose (30–40 mg) or low-dose (20–30 mg) DF (300 mg), each combined lamivudine efavirenz, for 48 weeks. Anthropometry, assessed using techniques. Results In all three treatment arms, there significant increase levels over study period. At weeks, fasting level (P < 0.005) homeostasis model assessment (HOMA) score (P < 0.05) increased significantly arm, as did insulin C-peptide both standard- arms. week 48, decrease adiponectin noted but an arm. In increases anthropometric measures occurred at 24 weeks decreased by 48. Mitochondrial toxicities Immunological virological outcomes similar arms. Conclusions This highlights occurrence metabolic abnormalities treatment. Awareness potential cardiovascular risk should be concern use therapies.